Oncology

Stomach pain
#Cancer treatment #Chemotherapy #Napo Pharmaceuticals #Oncology #Preclinical investigations #Puma Biotechnology

Prescription drug could prevent cancer therapy-related diarrhoea

A study in dogs has shown that crofelemer can provide symptomatic relief of diarrhoea associated with the irreversible pan-human epidermal growth factor receptor (HER) tyrosine kinase inhibitor (TKI) neratinib (Nerlynx). Puma Biotechnology’s Nerlynx is a pan HER TKI indicated for the extended adjuvant treatment of adult… Read More

#Cancer Research #News

#Breast cancer #Cancer research #Colorectal cancer #Leukaemia #Lung cancer #Oncology #Pancreatic cancer

New DDW Highlights podcast: 29 January 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  In the same week that it was revealed that breast cancer was the most… Read More

#News

RNA
#Business #FDA #mRNA #Oncology #Strand Therapeutics

Strand Therapeutics cuts workforce by 18%

Strand Therapeutics has announced an 18% cut to its workforce, just days after the US Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application to initiate a first-in-human trial of STX-001 for solid tumours. On LinkedIn the company said: “This week, Strand has… Read More

#Business & Investment #News #Trending News

#Breast cancer #Cancer research #Colorectal cancer #Leukaemia #Lung cancer #Oncology #Pancreatic cancer

This week in drug discovery (22-26 January) 

News round-up for 22-26 January by DDW Digital Content Editor Diana Spencer. In the same week that it was revealed that breast cancer was the most studied disease area in 2023 for the third year running, there were a number of promising developments in the treatment of colorectal,… Read More

#News

Blood cancer
#Acute Myeloid Leukaemia #FDA #Oncology #Orphan drugs #Pleco Therapeutics #Rare disease

Novel leukaemia drug receives FDA Orphan Drug Designation

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Pleco Therapeutics’s lead compound PTX-252 for the treatment of acute myeloid leukaemia (AML). PTX-252 is a novel molecular entity developed to increase the sensitivity of cancer cells to chemotherapy. The FDA’s… Read More

#Cancer Research #News #Regulatory

Bacteria
#Biomica #Cancer research #Immuno-oncology #Microbiome #Oncology #Phase I trial

Results for microbiome-based cancer drug expected H1 2024

Biomica has completed enrolment in its Phase I trial evaluating the safety and tolerability of its microbiome-based immuno-oncology drug, BMC128. Initiated in July 2022, the Phase I trial was designed to evaluate BMC128 in combination with immune checkpoint inhibitor (ICI) immunotherapy, in patients with either non-small… Read More

#Cancer Research #News

Pancreatic cancer
#Amplia Therapeutics #Australia #Cancer research #Oncology #Pancreatic cancer #Phase II trial

Phase IIa trial launches in advanced pancreatic cancer

The Phase IIa ACCENT trial has launched to explore the activity of focal adhesion kinase (FAK) inhibitor narmafotinib in combination with standard-of-care chemotherapy in advanced pancreatic cancer patients. In November 2023, Amplia Therapeutics announced completion of the Phase Ib stage of the ACCENT trial where ascending… Read More

#Cancer Research #News

Patient using a mammography machine
#Breast cancer #Cancer research #Clinical trial design #Clinical trials #Oncology #Phase II trial #Phesi

Breast cancer most researched disease area for third year running

Breast cancer was the most studied disease in 2023 for the third consecutive year, followed by solid tumours, stroke, Covid-19 and prostate cancer. The analysis of 65,749 recruiting clinical trials was conducted by data analytics company Phesi, as part of an annual global analysis of clinical… Read More

#Cancer Research #News #Trending News

Pancreatic cancer
#AI #ASCO #Cancer research #Clinical trials #FDA #Neurology #Oncology #Orphan drugs #Pancreatic cancer #Rare disease

Phase IIa results for combination pancreatic cancer therapy  

BPGbio, an AI-powered biopharma that focuses on oncology, neurology, and rare diseases, has announced new data from a Phase IIa clinical trial of its lead candidate, BPM31510, in patients with advanced pancreatic cancers at the annual ASCO Gastrointestinal Cancers Symposium, being held 18-20 January 2024, in San Francisco. Read More

#Cancer Research #News

Blood cells
#Blood cancer #Gene mutation #Oncology #University of Cambridge #Wellcome Sanger Institute

Study reveals how genetic mutations combine to cause cancer

UK scientists have uncovered the interplay between cancer-driving genetic mutations and inherited genetic variants in a rare type of blood cancer. In the future, this knowledge could aid drug development and interventions that reduce the risk of disease. Researchers from the Wellcome Sanger Institute,… Read More

#Cancer Research #News

European map
#Advanced Therapies Europe #Biologics / Biotechnology #Cancer immunotherapy #CAR-T #Cell and gene therapy #Cell therapy #Collaboration #Europe #Immuno-oncology #Market reporting #Oncology #Start-ups

New podcast: Why is Europe a drug discovery epicentre?

This is the latest episode of the free DDW narrated podcast, titled “Revolutionary technology for drug discovery and development” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: European drug discovery and development success stories,… Read More

#News

#Cancer #Diagnostics #Drug discovery #Oncology #Precision medicine

Can liquid biopsies transform precision medicine?

Brett Swansiger, Chief Commercial Officer at ANGLE, discusses the importance of liquid biopsies in precision medicine trials for cancer.   Challenges in the oncology clinical trials space The oncology market is a key growth driver for the pharma industry, with global drug revenues expected to reach US$390 billion by… Read More

#Cancer Research #Exclusive Content

#CAR-T #FDA #MHRA #Monoclonal antibodies #NMPA #Oncology #Regulatory

New DDW Highlights podcast: 15 January 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  This week has seen a number of significant discoveries by researchers in academic institutions,… Read More

#News

Merck HQ
#Harpoon Therapeutics #Immunotherapy #Merck #Mergers and acquisitions #Oncology

Merck continues to boost oncology pipeline through acquisitions

Merck (MSD), through a subsidiary, has agreed to acquire immunotherapy company Harpoon Therapeutics for $680 million. The acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumours. The announcement… Read More

#Business & Investment #News

#CAR-T #FDA #MHRA #Monoclonal antibodies #NMPA #Oncology #Regulatory

This week in drug discovery (8-12 January) 

News round-up for 8-12 January by DDW Digital Content Editor Diana Spencer. This week has seen a number of significant discoveries by researchers in academic institutions, in some cases in partnership with industry, emphasising the important role universities play in early-stage drug discovery. Perhaps most importantly,… Read More

#News